MNG55
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.237
- INFLAMMATORY_RESPONSE+0.226
- COAGULATION+0.204
- WNT_BETA_CATENIN_SIGNALING+0.197
- INTERFERON_GAMMA_RESPONSE+0.195
- KRAS_SIGNALING_DN+0.188
- KRAS_SIGNALING_UP+0.185
- UV_RESPONSE_DN+0.183
- INTERFERON_ALPHA_RESPONSE+0.160
- HEDGEHOG_SIGNALING+0.154
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.592
- MYC_TARGETS_V2-0.476
- MYC_TARGETS_V1-0.446
- UNFOLDED_PROTEIN_RESPONSE-0.412
- MTORC1_SIGNALING-0.391
- DNA_REPAIR-0.381
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.364
- ADIPOGENESIS-0.357
- PROTEIN_SECRETION-0.357
- GLYCOLYSIS-0.326
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1338301 | GTEX | — | 0.878 |
| 2 | SRR27320694 | — | — | 0.858 |
| 3 | SRR1321674 | GTEX | — | 0.856 |
| 4 | SRR615515 | GTEX | — | 0.854 |
| 5 | SRR1358689 | GTEX | — | 0.853 |
| 6 | ec48e2b8-ca0a-40fe-a87b-f0e955466840 | — | — | 0.852 |
| 7 | MNG690 | — | — | 0.849 |
| 8 | BS_NH7K4CD9 | EPN | Posterior Fossa EPN | 0.847 |
| 9 | SRR1328035 | GTEX | — | 0.846 |
| 10 | SRR1475803 | GTEX | — | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.237 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.226 | Idelalisib | — uncovered |
| COAGULATION | 0.204 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.197 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.195 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.188 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.185 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.183 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.160 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.154 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.132 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.128 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.127 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.122 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.098 | Inavolisib | — uncovered |
| MYOGENESIS | 0.093 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.061 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.049 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.023 | Idelalisib | — uncovered |